News

This collaboration aims to harness Invenra’s B-Body bispecific antibody platform to advance Astellas’ research and development in antibody discovery. Invenra CEO Dr Roland Green said: “We are honoured

This approval introduces a once-daily, oral, two-drug regimen for individuals aged 12 years and above, weighing a minimum of 25kg. Dovato, which combines dolutegravir (50mg) with lamivudine (300mg),

This designation is based on results from the global multi-center Phase I/II study, WU-KONG1. The BTD was awarded following the presentation of results at the 2023 ESMO conference,

The deal focuses on a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars are gaining recognition for their potential to offer cost-effective alternatives

The funds will be channelled towards advancing multiple proprietary pipeline programmes into clinical trials, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor. This significant

This development creates new pathways for the vaccine’s procurement, distribution, and reimbursement by both public and private payers. In response to the global mpox outbreak, since 2022, JYNNEOS

Duchenne is a genetic disorder, primarily affecting boys and is known to be fatal. This disease is claimed to affect roughly one in every 3,500 to 5,000 live

Utidelone’s unique properties allow it to cross the blood-brain barrier (BBB), a capability supported by both preclinical and clinical studies. A Phase II study involving utidelone in combination

This sNDA extends the indication of Vemlidy, a once a day 25mg tablet for usage in children aged six years and above weighing a minimum of 25kg with